# US 2021/0261690 A9 · Method of Generating Anti-Linaclotide Antibodies and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261690 A9
- Document ID: US20210261690A9
- Status: Published application
- Kind: A9
- Application number: 16/407,457
- Filed: 2019-05-09
- Published: 2021-08-26
- Earliest claimed: 2018-05-11
- Assignees: Ironwood Pharmaceuticals, Inc.
- Applicants: Ironwood Pharmaceuticals, Inc.
- Inventors: Wilmin Bartolini; Marco Kessler
- Web page: https://patentgrep.com/patent/US20210261690A9

## CPC

- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07K 1/042: {characterised by the nature of the carrier}
- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides a method for producing anti-linaclotide antibodies or antigen fragments thereof and uses thereof.

## Claims

### Claim 1

A antibody or antigen-binding fragment thereof that binds to an epitope of linaclotide.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the epitope comprises the C-terminal tyrosine of linaclotide.

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the epitope comprises the amino acid sequence: Cys Thr Gly Cys Tyr.

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof is conjugated to a detectable label.

### Claim 5 (depends on 4)

The antibody or antigen-binding fragment thereof of claim 4, wherein the detectable label comprises an enzyme, a radiolabel, a peptide, a linker, a fluorescent molecule, or a chemiluminescent molecule.

### Claim 6 (depends on 4)

The antibody or antigen-binding fragment thereof of claim 4, wherein the detectable label is a fluorescein-containing label.

### Claim 7 (depends on 4)

The antibody or antigen-binding fragment thereof of claim 4, wherein the detectable label is SULFO-TAG.

### Claim 8 (depends on 4)

The antibody or antigen-binding fragment thereof of claim 4, wherein the detectable label is a peptide selected from the group consisting of Cy3, Cy5, His6, Myc-tag, GST-tag, and maltose binding protein.

### Claim 9 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody is a polyclonal, monoclonal, chimeric, humanized, or human antibody.

### Claim 10 (depends on 9)

The antibody or antigen-binding fragment thereof of claim 9, wherein the antibody is a polyclonal antibody.

### Claim 11 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the antigen binding fragment thereof is an Fab, F(ab′)2, scFv, Fab′-SH, diabody, triabody, or linear antibody.

### Claim 12 (depends on 1)

A method for detecting linaclotide in a biological specimen which comprises:
a) contacting the specimen with a first antibody or antigen-binding fragment thereof, wherein the first antibody is the antibody or antigen binding fragment of claim 1, thereby forming a complex between linaclotide and the first antibody or antigen-binding fragment thereof; and
b) assaying for the presence of the complex.

### Claim 13 (depends on 12)

The method of claim 12, wherein the biological specimen is human plasma.

### Claim 14 (depends on 12)

The method of claim 12, wherein the biological specimen is selected from the group consisting of human serum, intestinal luminal fluid, fecal matter, urine, saliva, tissue and cells.

### Claim 15 (depends on 12)

The method of claim 12, wherein assaying for the presence of the complex comprises contacting the complex with a detectable label.

### Claim 16 (depends on 15)

The method of claim 15, wherein the detectable label is SULFO-TAG.

### Claim 17 (depends on 15)

The method of claim 15, wherein assaying for the presence of the complex comprises the addition of a second antibody to the complex, wherein said antibody specifically binds to the first antibody or antigen-binding fragment thereof in the complex.

### Claim 18 (depends on 17)

The method of claim 17, wherein the second antibody is conjugated to a detectable label.

### Claim 19 (depends on 17)

The method of claim 17, wherein the second antibody is an antibody conjugated with horseradish peroxidase.

### Claim 20 (depends on 18)

The method of claim 18, wherein the detectable label is fluorescein.

### Claim 21

A method of producing anti-linaclotide antibodies comprising:
a) conjugating linaclotide to a carrier protein;
b) immunizing an animal with the protein conjugated linaclotide to produce an immune response and thereby generate anti-linaclotide antibodies; and
c) harvesting the anti-linaclotide antibodies from the immunized animal.

### Claim 22 (depends on 21)

The method of claim 21, wherein the N-terminus of linaclotide is covalently bound to the carrier protein.

### Claim 23 (depends on 21)

The method of claim 21, wherein the linaclotide is reduced.

### Claim 24 (depends on 21)

The method of claim 21, wherein the carrier protein is a dipalmitoyl-containing protein.

### Claim 25 (depends on 21)

The method of claim 21, wherein the carrier protein is a T-Cell epitope heterodimer.

### Claim 26 (depends on 21)

The method of claim 21, wherein the carrier protein is Bovine Serum Albumin (“BSA”).

### Claim 27 (depends on 21)

The method of claim 21, wherein the carrier protein is Keyhole Limpet Hemocyanin (“KLH”).

### Claim 28 (depends on 21)

The method of claim 21, further comprising d) purifying the anti-linaclotide antibodies.

### Claim 29 (depends on 21)

The method of claim 21, wherein purifying comprises affinity chromatography.

### Claim 30

A method of detecting an antibody or antigen-binding fragment of linaclotide in a biological specimen which comprises:
a) contacting the specimen with linaclotide or epitope thereof, wherein the linaclotide or epitope thereof is conjugated or bound to a detection label, tag, or substrate, thereby forming a complex between linaclotide and the antibody or antigen-binding fragment thereof of linaclotide; and
b) assaying for the presence of the complex.

### Claim 31 (depends on 30)

The method of claim 30, wherein assaying for the presence of the complex comprises performing an assay selected from the group consisting of dot membrane (dot blot) assay, enzyme-linked immunosorbent assay (ELISA), Fluorescence-linked immunosorbent assay (FLISA) and electrochemiluminescence.

### Claim 32 (depends on 30)

The method of claim 30, further comprising conjugating the antibody or antigen-binding fragment thereof of linaclotide with a detection label before contacting the specimen with linaclotide or epitope thereof.

### Claim 33

A method for qualifying a manufacturing batch of linaclotide comprising;
a) providing a batch of linaclotide;
b) contacting at least a portion of the batch of linaclotide with anti-linaclotide antibodies or antigen-binding fragment, thereby forming a complex between linaclotide and anti-linaclotide antibodies or antigen-binding fragments thereof;
c) quantifying the presence of said complex; and
d) correlating the quantity of said complex with a known quantity of complex formed between a reference batch of linaclotide and anti-linaclotide antibodies or antigen-binding fragment thereof.

### Claim 34 (depends on 33)

The method of claim 33, wherein the anti-linaclotide antibodies or antigen-binding fragment is conjugated to a detectable label.

### Claim 35 (depends on 34)

The method of claim 34, wherein the detectable label comprises an enzyme, a radiolabel, a peptide, a linker, a fluorescent molecule, or a chemiluminescent molecule.
